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A B S T R A C T
Lipotoxicity causes hepatic cell death and therefore plays an important role in the pathogenesis of non-alcoholic
fatty liver disease (NAFLD). Metformin, a first-line anti-diabetic drug, has shown a potential protective effect
against NAFLD. However, the underlying mechanism is still not clear. In this study, we aim to understand the
molecular mechanism of the protective effect of metformin in NAFLD, focusing on lipotoxicity. Cell death was
studied in HepG2 cells and primary rat hepatocytes exposed to palmitate and metformin. Metformin ameliorated
palmitate-induced necrosis and apoptosis (decreased caspase-3/7 activity by 52% and 57% respectively) in
HepG2 cells. Metformin also reduced palmitate-induced necrosis in primary rat hepatocytes (P < 0.05). The
protective effect of metformin is not due to reducing intracellular lipid content or activation of AMPK signaling
pathways. Metformin and a low concentration (0.1 μmol/L) of rotenone showed moderate inhibition on mi-
tochondrial respiration indicated by reduced basal and maximal mitochondrial respiration and proton leak in
HepG2 cells. Moreover, metformin and rotenone (0.1 μmol/L) preserved mitochondrial membrane potential in
both HepG2 cells and primary rat hepatocytes. In addition, metformin and rotenone (0.1 μmol/L) also reduces
reactive oxygen species (ROS) production and increase superoxide dismutase 2 (SOD2) expression. Our results
establish that metformin AMPK-independently protects against palmitate-induced hepatic cell death by mod-
erate inhibition of the mitochondrial respiratory chain, recovering mitochondrial function, decreasing cellular
ROS production, and inducing SOD2 expression, indicating that metformin may have beneficial actions beyond
its glucose-lowering effect and also suggests that mitochondrial complex Іmay be a therapeutic target in NAFLD.
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the
major health problems around the world and its prevalence coincides
with the unprecedented increase of obesity in recent decades. NAFLD is
characterized as increased accumulation of lipids in the liver and its
severity ranges from simple steatosis to non-alcoholic steatohepatitis
(NASH). In the last few decades, our knowledge about the role of lipids
in the pathogenesis of NAFLD has increased substantially. It has been
shown that elevated plasma levels of non-esterified fatty acids (NEFA)
are closely associated with hepatic dysfunction and consequently, the
detrimental effect of surplus lipids, especially saturated fatty acids, has
been termedlipotoxicity [1,2]. Both in vivo experiments and clinical
studies indicated that the saturated fatty acids are more toxic compared
to unsaturated fatty acids and therefore saturated fatty acids may be
one of the factors promoting the progression of steatosis to steatohe-
patitis [3,4]. Thus, counteracting lipotoxicity has become one of the
therapeutic targets in the treatment of NAFLD.
Studies have shown that hepatic cell death represents the major
consequence of lipotoxicity in the liver. Hepatic cell death is preceded
or associated with a broad spectrum of subcellular dysfunctions, in-
cluding endoplasmic reticulum (ER) stress, mitochondrial dysfunction,
oxidative stress, autophagy, disturbed signaling pathways, etc. [1,2,5]
Several studies highlighted the increased mitochondrial activity of
NAFLD patients and hypothesized that the accelerated mitochondrial
metabolism could be responsible for the elevated generation of ROS
[6–9]. However, it is still not completely clear what the role of mi-
tochondria is in lipotoxicity and the pathogenesis of NAFLD.
Metformin, as one of the first-line anti-diabetic medicines, showed
beneficial effects against hepatic cell death. Our group has previously
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reported that metformin prevents both bile acid and oxidative stress-
induced hepatic injury [10,11]. Accumulating evidence indicates that
the activation of AMP-dependent protein kinase (AMPK) plays a central
role in the actions of metformin. For instance, metformin-induced im-
provement in insulin action is AMPK dependent [12]. On the other
hand, some of the effects of metformin are AMPK independent. For
example, our previous studies showed that the protective effect of
metformin against bile-acid induced hepatic injury does not require
AMPK/mTOR-signaling [10]. Furthermore, the actions of metformin
could also be closely related to its inhibition of the mitochondrial re-
spiration chain complex Ι [13,14]. Taken together, the exact molecular
mechanisms of metformin are still not clear.
In the present study, we aim to evaluate the protective effect of
metformin against lipotoxicity and investigate the underlying me-
chanisms.
2. Materials and methods
2.1. Cell culture and infection
HepG2 cells were obtained from American Type Culture Collection
and maintained with Dulbecco's Modified Eagle Medium (DMEM, Life
Technologies, Breda, The Netherlands) supplemented with 10% fetal
calf serum (Invitrogen, Breda, The Netherlands), 100 U/mL penicillin,
100μg/mL streptomycin and 250 ng/mL fungizone (1% PSF, Lonza,
Verviers, Belgium) at 37 °C in a 5% (v/v) CO2 condition. During ex-
periments, cells were cultured in serum-free medium. Before infection,
HepG2 cells were seeded on plates and grown to 60% confluence and
then infected with dominant negative AMPK-adenovirus (ad-DN-
AMPK) or control β-galactosidase-adenovirus (ad-LacZ). Ad-DN-AMPK
and ad-LacZ were kindly provided by Dr. Birnbaum [15]. After 24 h of
infection, cells were treated with or without metformin (1,1-dimethyl
biguanide hydrochloride, Sigma-Aldrich) for 60 min, and harvested to
determine p-AMPK expression; or cells were pretreated with metformin
for 30 min and exposed to palmitate and then harvested for caspase-3/7
assay.
2.2. Animals and primary hepatocyte isolation
Specified pathogen-free male Wistar rats (180–250 g) were pur-
chased from Charles River Laboratories Inc. (Wilmington, MA, USA).
Rats were housed under standard laboratory conditions with free access
to standard laboratory chow and water. All experiments were per-
formed according to the Dutch law on the welfare of laboratory animals
and guidelines of the ethics committee of University of Groningen for
care and use of laboratory animals.
Hepatocytes were isolated from male Wistar rats by two-step col-
lagenase perfusion method as described previously [16] and cultured in
William's E medium (Invitrogen, Breda, the Netherlands) supplemented
with 50 μg/mL gentamicin (Invitrogen) at 37 °C in a 5% (v/v) CO2
condition. Experiments were started after an attachment period of 4 h.
2.3. Preparation of palmitate-BSA and stearate-BSA
BSA-conjugated palmitate or stearate solution (palmitate/stearate)
was prepared by modification of the seahorse protocol (Seahorse
Bioscience). A 40 mmol/L palmitate/stearate (Sigma-Aldrich) solution
was prepared at 70 °C. After dissolving, the solution was complexed
with 10% fatty acid-free BSA (Sigma-Aldrich) at an 8:1 palmitate/
stearate to BSA molar ratio. Then the BSA-conjugated palmitate/stea-
rate solution was added to serum-free cell culture medium to achieve a
final palmitate/stearate concentration of 0.5 mmol/L or 1.0 mmol/L.
The pH was adjusted to 7.4 by addition of 1 M NaOH.
2.4. Sytox green nuclear staining
After exposure to palmitate in the presence and absence of met-
formin or rotenone, HepG2 cells were incubated with Sytox green nu-
cleic acid dye (Invitrogen) for 15 min as described before to determine
necrotic cell death [10]. Fluorescent nuclei were visualized using a
Leica DMI6000 at 450–490 nm.
2.5. Determination of mitochondrial membrane potential
JC-10 staining: mitochondrial membrane potential (Δψm) was as-
sessed via JC-10 (Sigma-Aldrich) staining. In normal cells, JC-10 con-
centrates in the mitochondrial matrix where it forms red fluorescent
aggregates. However, when the mitochondrial membrane becomes
polarized, JC-10 diffuses out of mitochondria and remains monomer
which has a green to greenish orange emission. The mitochondrial
membrane potential was shown as the ratio of JC-10 aggregates over
monomers. Fluorescence was visualized using a Leica DMI6000 at
570 nm and 490 nm. Images were analyzed by ImageJ (ImageJ;
National Institutes of Health, Bethesda, MD, USA, http://rsbweb.nih.
gov/ij/).
TMRE staining: mitochondrial membrane potential (Δψm) was as-
sessed by flow cytometry using TMRE (Tetramethylrhodamine ethyl
ester perchlorate, T669, Invitrogen) fluorescent dye. Briefly, HepG2
cells and primary rat hepatocytes were harvested and incubated with
200 nmol/L TMRE or PBS for 20 min at 37 °C (the latter allows for
autofluorescence determination). Then, the cells were centrifuged and
resuspended in PBS. Cells treated with FCCP (carbonyl cyanide-4-(tri-
fluoromethoxy) phenylhydrazone, 50 μmol/L) for 30 min were used as
a positive control. Samples were analyzed via CytoFLEX S benchtop
flow cytometer (Beckman Coulter Life Sciences). TMRE fluorescence
was excited at 488 nm and detected at 585/42 nm. Data were processed
using Flowjo software (Becton, Dickinson & Co).
2.6. Lactate dehydrogenase (LDH) release assay
Necrotic cell death was quantified by LDH measurement, described
previously by Woudenberg-Vrenken et al. [17]. Briefly, the LDH release
was calculated as the percentage of the activity of LDH released in the
medium vs. the total LDH activity (in both the medium and cell lysates).
The LDH activity was measured spectrophotometrically at 340 nm
using a Bio-Tek Epoch2 microplate reader (Bio-Tek Instruments, Inc.,
Bad Friedrichshall, Germany).
2.7. Caspase-3/7 enzyme activity assay
Cells were harvested at indicated time points and washed twice with
ice-cold phosphate buffered saline (PBS, Life technologies) before ad-
dition of caspase cell lysis buffer. Total cell lysates were prepared and
caspase-3/7 activity was determined as described previously [10].
2.8. ROS measurement
HepG2 cells were seeded on 96-well plates. After 24 h of culture, the
medium was replaced with medium containing palmitate and cells were
treated with metformin or rotenone. Dihydroethidium (DHE, Life
technology) fluorescence method was used for determination of ROS
levels. After treatment, cells were incubated with 5 μmol/L DHE for
30 min in dark. Fluorescence was recorded at Ex/Em 518/605 using a
Bio-Tek FL600 microplate fluorescent reader (Bio-Tek, Germany).
2.9. Oil Red O staining and triglyceride determination
Lipid droplets were visualized by Oil Red O staining. Cells were
seeded on coverslips. After culturing, cells were rinsed with PBS and
fixed with 4% (v/v) formaldehyde for 20 min at room temperature.
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After washing with distilled water, cells were incubated with 60% (v/v)
isopropyl alcohol and then mounted with oil red O solution (Sigma-
Aldrich, dissolved in isopropyl alcohol). Then cells were rinsed in dis-
tilled water, 60% (v/v) isopropyl alcohol, counterstained with hema-
toxylin, rinsed with tap water, and sealed with glycerin-gelatin. The
coverslips were scanned and the lipid droplets identified by their red
staining.
To quantify the lipid accumulation, triglyceride levels in cells were
measured using a triglyceride measurement kit (Abcam, UK) following
the guideline provided by the company. The amount of triglyceride was
normalized to the number of cells.
2.10. Western blot analysis and antibodies
To evaluate the expression of specific proteins, the total cell lysate
was subjected to Western blot as described by Woudenberg-Vrenken
et al. [10]. Proteins were detected using the following antibodies: p-
AMPKα (Thr172) (Cell Signaling, Danvers, MA, USA), p-eIF2α(Cell
Signaling Technology, Danvers, MA, USA) eIF2α (Cell Signaling Tech-
nology, Danvers, MA, USA) and PARP (Cell Signaling Technology,
Danvers, MA, USA) at a dilution of 1:1000. Monoclonal mouse anti-
bodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
Calbiochem, San Diego, CA, USA) at a dilution of 1:50,000 were used to
ensure equal protein loading.
2.11. Monitoring of mitochondrial metabolism by Seahorse
The oxygen consumption rate (OCR) was measured by Seahorse
system. HepG2 cells were initially seeded in XF24 cell culture plates at
1 × 105 cells/well and primary hepatocytes at 5 × 104 cells/well. After
challenging with palmitate in the presence and absence of metformin or
rotenone, cells were washed with PBS and XF assay medium supple-
mented with 1 mmol/L sodium pyruvate and incubated in a non-CO2
incubator at 37 °C for 60 min. OCR was measured with XF24
Extracellular Flux Analyzer (Seahorse Bioscience, Inc., Billerica, MA,
USA) using manufacturer recommended protocols. After normalization
to protein concentration, basal respiration, proton leak and maximal
respiration were calculated, Specifically, the basal respiration is cal-
culated without glucose and all rates were corrected for non-mi-
tochondrial OCR. An illustration graph is shown in Fig. 5A.
2.12. RNA isolation and quantitative polymerase chain reaction
Total RNA was isolated using Tri-reagent (Sigma-Aldrich) according
to the manufacturer's instruction. The RNA quantity and quality were
measured with the Nanodrop spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). 2.5 μg RNA was used for reverse transcription.
Quantitative real-time PCR was performed with the 7900HT Fast Real-
time System (Applied Biosystems) using the TaqMan method or SYBR
Green method. mRNA levels were normalized to 18S and then further
normalized to the expression of control groups. The primers and probes
are shown in Table 1.
2.13. Luciferase-based ATP measurement
Luminescent ATP detection assay kit (Promega, USA) was used to
measure ATP production in HepG2 cells. In brief, 1 × 104 cells/well
were seeded in 96 well plates following the instructions provided by the
company. Luminescence from luciferase activity was measured and
recorded using a Bio-Tek FL600 microplate fluorescent reader (Bio-Tek,
Germany).
2.14. Immunofluorescence microscopy
HepG2 cells were seeded on coverslips. At the end of the experi-
ments, cells were fixed with 4% paraformaldehyde (Merck Millipore)
and permeabilized with 1% Triton X-100 followed by blocking with 1%
BSA. Then cells were incubated with the primary antibody anti-SOD2
(Enzo Life Sciences, Brussels, Belgium) and labeled with secondary
antibodies Alexa Fluor 488 (Invitrogen). The coverslips were mounted
in fluorescence mounting medium supplemented with anti-fading agent
DAPI (Vector Laboratories, Inc., Peterborough, UK). Images were cap-
tured using a Leica DMI6000 microscope and analyzed by ImageJ.
2.15. Statistical analysis
All results are presented as a mean of at least 3 independent
experiments± S.D. For each experiment, statistical analyses were per-
formed using the one-way ANOVA test, followed by Tukey's multiple
comparison tests or Mann Whitney test; P < 0.05 was considered as
statistically significant.
3. Results
3.1. Metformin protects HepG2 cells from palmitate and stearate-induced
cell death in both HepG2 cells and primary rat hepatocytes
Palmitate dose-dependently induced caspase-3/7 activity in HepG2
cells (Supplemental Fig. 1A) and a pathophysiologically relevant con-
centration of palmitate (0.5 mmol/L) was used for subsequent experi-
ments [18]. Palmitate time-dependently induced caspase-3/7 activity
peaking at 16 h after exposure (Supplemental Fig. 1B). Therefore, the
effect of metformin and rotenone on palmitate-induced caspase-3/7
activity was measured at 16 h, whereas staining for necrosis using Sytox
green (an endpoint assay) was determined at 24 h. Gene expression
analysis and mitochondria-related experiments were performed after
12 h or 16 h of palmitate exposure.
Metformin (1.0 mmol/L) inhibited palmitate (0.5 mmol/L) induced
necrotic cell death in HepG2 cells, as shown by the reduction of Sytox
Green staining (Fig. 1A). The inhibition of necrosis was quantified by
LDH release measurement. Palmitate increased LDH release and met-
formin inhibited it by 52% (P < 0.01) (Fig. 1B). Moreover, metformin
reduced palmitate-induced apoptotic cell death as shown by a reduction
of caspase-3/7 activity (−57%, P < 0.001) (Fig. 1C) and a decreased
level of cleaved PARP (P < 0.001) (Fig. 1D). In addition, metformin
also inhibited palmitate-induced ROS generation in HepG2 cells
(P < 0.05) (Fig. 1E). These results imply that metformin protects
against both palmitate-induced necrotic and apoptotic cell death.
Table 1
Sequences of human primers and probes used for real-time PCR analysis.
Gene Sense 5′-3′ Antisense 5′-3′ Probe 5′-3′
18S CGGCTACCACATCCAAGGA CCAATTACAGGGCCTCGAAA CGCGCAAATTACCCACTCCCGA
SOD1 CTCACTTTAATCCTCTATCCAGAAAACA ATCTTTGTCAGCAGTCACATTGC CAACATGCCTCTCTTCATCCTTTGGCC
SOD2 TaqMan® Gene Expression Assay: Hs01553554-m1
CHOP GGAAATGAAGAGGAAGAATCAAAAAT GTTCTGGCTCCTCCTCAGTCA TTCACCACTCTTGACCCTGCTTCTCTGG
GRP78 TGGTGATCAAGATACAGGTGACCT GTGTTCCTTGGAATCAGTTTGGT TCCCCTTACACTTGGTATTGAAACTGTGGG
Gadd34 GGCTCAAGCGCCCAGAAACC AATGGACAGTGACCTTCTCG
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Additionally, we also examined the effect the metformin on stearate-
induced lipotoxicity. Metformin also significantly reduced stearate-in-
duced caspase 3/7 activity (P < 0.05) (Supplemental Fig. 3).
In primary rat hepatocytes, metformin also protected against pal-
mitate (1.0 mmol/L) induced necrotic cell death, as shown by the re-
duced Sytox Green staining (Fig. 1F) and reduced LDH release (−68%,
P < 0.05) (Fig. 1G).
3.2. Metformin does not reduce palmitate-induced lipid accumulation
Considering that metformin may affect lipid accumulation, we
checked the intracellular lipid content. As shown by Oil Red O staining,
metformin does not influence palmitate-induced lipid droplet formation
in both HepG2 cells and primary rat hepatocytes (Fig. 2A and C). The
lipid droplets were quantified by intracellular TG measurement, which
Fig. 1. Metformin (Met) inhibits palmitate-induced hepatic cell death and reduces intracellular ROS production.
(A) HepG2 cells were pretreated with metformin (1.0 mmol/L, −30 min), then exposed to palmitate (0.5 mmol/L, 24 h). Plasma membrane rupture indicative of
necrotic cell death is demonstrated by Sytox Green staining. Magnification 10×, scale bars 250 μm. (B and G) Necrosis is quantified by LDH release shown as a
percentage of total LDH release in the medium. (C) HepG2 cells were pretreated with metformin then exposed to palmitate (0.5 mmol/L, 16 h). Apoptosis is presented
as caspase-3/7 activity shown as fold induction compared to control values. Control values were set at 1. (D) After exposure to palmitate, protein levels of PARP, c-
PARP and GAPDH were measured by Western-blot and quantified from the immunoblots by densitometry from three independent experiments with ImageJ. (E)
Intracellular ROS production was measured 12 h after exposing to palmitate with or without pretreatment with metformin. ROS was measured by the intensity of
DHE emission. (F) Primary rat hepatocytes were pretreated with metformin (1.0 mmol/L, 30 min), then exposed to palmitate (1.0 mmol/L, 24 h). Necrotic cell death
is demonstrated by Sytox Green staining. Magnification 10×, scale bars 250 μm. * indicates P < 0.05; ** indicates P < 0.01; *** indicates P < 0.001.
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shows that metformin also does not reduce the amount of TG in both
HepG2 cells and primary rat hepatocytes (Fig. 2B and D). Thus, the
results indicate that the protective effect of metformin against palmitate
is not by reducing intracellular lipid content.
3.3. Metformin inhibits palmitate-induced eIF2α phosphorylation but does
not reduce CHOP, Gadd34 and GRP78 mRNA expression
It has been reported that palmitate induces ER stress and that
metformin may inhibit lipotoxicity by reducing ER stress [19,20]. In-
deed, we confirm that palmitate induced ER stress demonstrated by
increased p-eIF2α level and increased mRNA expression of CHOP,
GRP78 and Gadd34 (Fig. 3A and B). However, although metformin
significantly inhibited p-eIF2α (Fig. 3A), it did not reduce the mRNA
expression of CHOP, Gadd34 and GRP78, which are the downstream
target genes of p-eIF2α at both 12 and 16 h (Fig. 3B). Thus, the results
demonstrate that the dephosphorylation of p-eIF2α did not lead to
deactivation of the downstream UPR signaling pathways, indicating
that metformin does not directly reduce ER stress.
3.4. The protective effect of metformin is independent of AMPK activation
Metformin has been shown to activate APMK signaling to promote
cell survival [21]. Thus, in order to examine whether the protective
effect of metformin is AMPK related, HepG2 cells were infected with
dominant negative AMPK adenovirus. The expression of p-AMPK was
significantly decreased at 24 h after infection and metformin was not
able to activate AMPK (Fig. 3C). Importantly, metformin could still
inhibit palmitate-induced caspase-3/7 activation to the same extent
compared to cells with an intact AMPK environment (−52%,
P < 0.001) (Fig. 3C and D). Therefore, we conclude that the protective
effect of metformin is independent of AMPK signaling.
Fig. 2. Metformin does not reduce intracellular lipid content.
Cells were pretreated with metformin (1.0 mmol/L) for 30 min, then exposed to palmitate (HepG2 cells: 0.5 mmol/L; primary rat hepatocytes: 1.0 mmol/L) for 12 h.
(A and C) Lipid droplets were stained by Oil Red O staining. Magnification 20×, scale bars 100 μm. (B and D) intracellular triglyceride content was quantified. ns
indicates P > 0.05.
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3.5. A low, but not high, concentration of rotenone protects against
palmitate-induced cell death and reduces ROS production
Metformin has been suggested to mediate its effects in part by in-
hibiting the mitochondrial respiratory chain complex Ι [13,14,22].
Therefore, we also investigated the effect of rotenone, a known in-
hibitor of mitochondrial respiratory chain complex Ι. Interestingly, our
results showed that a low concentration of rotenone (0.1 μmol/L) in-
hibited palmitate-induced necrosis and apoptosis, whereas a high con-
centration of rotenone (1.0 μmol/L) failed to inhibit palmitate-induced
necrosis and apoptosis (Fig. 4A and B). In addition, the intracellular
ROS generation correlated with necrosis and apoptosis: rotenone re-
duced ROS production at 0.1 μmol/L but failed to reduce ROS gen-
eration at 1.0 μmol/L (Fig. 4C). These results demonstrated that the
inhibition of mitochondrial complex Ι has critical effects on palmitate-
induced toxicity.
3.6. Metformin protects against palmitate-induced cell death by partial
inhibition of mitochondrial respiratory chain complex Ι
Given the divergent effects of low and high concentrations of rote-
none on palmitate-induced cell death, the Seahorse Analyzer was used
to explore the effects of metformin and rotenone on mitochondrial re-
spiration. In HepG2 cells, metformin partially inhibited mitochondrial
respiration and decreased both basal and maximal mitochondrial re-
spiration (−36% (P < 0.05) and −43% respectively) (Fig. 5B). The
low, protective concentration of rotenone (0.1 μmol/L) has a similar
effect on mitochondrial respiration, indicated by similar reductions of
basal and maximal mitochondrial respiration (−41% (P < 0.05) and
−46% respectively) (Fig. 5C). However, the high, toxic concentration
of rotenone (1.0 μmol/L) strongly blocked the mitochondrial re-
spiratory chain, as shown by the sharp reduction of both basal and
maximal mitochondrial respiration (−86% (P < 0.001) and −88%
(P < 0.0001) respectively) (Fig. 5C). In addition, as shown in Fig. 6C,
metformin and the low dose of rotenone slightly but non-significantly
reduced cellular ATP production (P > 0.05), however, the high dose of
rotenone significantly impaired the cellular ATP production
(P < 0.05).
In primary rat hepatocytes, palmitate severely impaired mitochon-
drial respiration and metformin was shown to restore the impaired
mitochondrial respiration, demonstrated by improved responsiveness to
oligomycin, FCCP and Rot/AA and recovery of maximal respiration
(P > 0.05) (Fig. 5E and F).
These results indicate that metformin and rotenone (0.1 μmol/L)
may protect against palmitate-induced hepatic cell death by partially
inhibiting mitochondrial respiratory chain complex Ι without sig-
nificantly impairing cellular ATP production. On the other hand, a
complete blockage of the mitochondrial respiratory chain has no pro-
tective effect and in fact, appears to aggravate palmitate-induced cel-
lular damage.
3.7. Metformin and rotenone (0.1 μmol/L) restore mitochondrial function
and induce mitochondrial SOD2 expression
Mitochondria play a key role in regulating cellular energetics and
activating the intrinsic pathway of cell death signaling. Thus, we de-
termined the mitochondrial function by measuring the mitochondrial
membrane potential, a marker of mitochondrial integrity. In HepG2
cells, palmitate caused mitochondrial depolarization as indicated by the
decrease of the JC-10 aggregates/monomers ratio, while metformin and
rotenone (0.1 μmol/L) significantly restored mitochondrial function as
shown by the recovery of the JC-10 aggregates/monomer ratio
(P < 0.05, Fig. 6A and B). However, the high concentration of rote-
none (1.0 μmol/L) did not reverse mitochondrial membrane
Fig. 3. Metformin inhibits the phosphorylation of eIF2α but does not reduce CHOP, GRP78 and Gadd45 mRNA expression and its protective effect is not dependent
on the activation of AMPK signaling.
(A) HepG2 cells were pretreated with metformin (1.0 mmol/L) for 30 min, then exposed to palmitate (0.5 mmol/L) for 12 h. The level of p-eIF2α, eIF2α and GAPDH
were measured by Western-blot. Levels of eIF2α/ p-eIF2α were quantified from the immunoblots by densitometry from three independent experiments with ImageJ.
(B) After 12 and 16 h of exposure to palmitate, the mRNA levels of CHOP, GRP78 and Gadd34 were evaluated by real-time quantitative PCR. (C) HepG2 cells were
infected with either Ad-DN-AMPK or Ad-LacZ for 24 h, then treated with or without metformin for 1 h. p-AMPK and GAPDH protein were detected by Western-blot.
(D) After infection with the adenovirus, HepG2 cells were exposed to palmitate (16 h post-infection) in the presence and absence of metformin. Caspase-3/7 activity
was determined. Data were shown as mean ± S.D. (n ≥ 3). * Indicates P < 0.05, ns indicates P > 0.05.
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depolarization (P > 0.05, Fig. 6B). In addition, we also used the TMRE
method with FACS to confirm the effect of metformin and rotenone on
mitochondrial membrane potential. Using TMRE FACS analysis, pal-
mitate decreased mitochondrial membrane potential as shown by a
decreased percentage of TRME positive cells, while metformin (non-
significantly, P = 0.07) and rotenone (0.1 μmol/L) (significantly,
P < 0.05) restored mitochondrial membrane potential (Supplemental
Fig. 4A and B). In contrast, rotenone at 1.0 μmol/L failed to restore
mitochondrial polarization (P > 0.05, Supplemental Fig. 4B). More-
over, in primary rat hepatocytes, palmitate also caused mitochondrial
depolarization and metformin significantly restored the mitochondrial
depolarization (P = 0.05, Supplemental Fig. 4C). These results indicate
that metformin and rotenone (0.1 μmol/L) recover the mitochondrial
function in hepatocytes.
As shown in Figs. 1E and 4C, palmitate increased intracellular ROS
generation, while both metformin and rotenone (0.1 μmol/L) reduced
proton leak and decreased ROS generation. Therefore, the effects of
metformin and rotenone (0.1 μmol/L) on antioxidant enzymes were
investigated. We found that both metformin and rotenone induced
SOD2 mRNA expression but did not induce SOD1 mRNA expression
(Fig. 7A). Moreover, the protein level of SOD2 was also increased in
mitochondria by metformin and rotenone (0.1 μmol/L) in HepG2 cells
as shown by immunofluorescence (Fig. 7B). Furthermore, exogenous
cell-permeable SOD (PEG-SOD, 100 U/mL) significantly reduced pal-
mitate-induced caspase 3/7 activity (P < 0.05) (Fig. 7C). These results
confirmed that metformin and rotenone (0.1 μmol/L) restored mi-
tochondrial function and might prevent ROS accumulation by inducing
SOD2 expression.
4. Discussion
In the present study, we showed that metformin protected hepato-
cytes from palmitate-induced cell death. The protective effect of met-
formin was mimicked by a low dose of the mitochondrial complex І
inhibitor rotenone (0.1 μmol/L). Moreover, metformin and rotenone
represented similar protective effects: both metformin and rotenone
(0.1 μmol/L) partially inhibited mitochondrial respiration, restored
mitochondrial membrane potential, reduced ROS production and in-
duced SOD2 expression. Therefore, it is likely that metformin protects
against palmitate-induced cell death by partially inhibiting mitochon-
drial complex І, thus restoring mitochondrial function. Of note, the
protective effect of metformin was independent of AMPK signaling or
reduction of lipid accumulation. The latter result differs from Woo et al.
who reported a reduction of lipid accumulation in a hepatoma cell line
by metformin [23]. However, in that study, lipid accumulation was
assessed by Oil Red O staining only and not quantitated or statistically
analyzed. We did quantitate lipid accumulation in HepG2 cells by
measuring triglyceride content as well.
The protective effects of metformin was observed in both the he-
patoma cell line HepG2 as well as in primary rat hepatocytes. HepG2
Fig. 4. Rotenone at 0.1 μmol/L protected against palmitate-induced cell death and reduced ROS production, but not at 1.0 μmol/L.
(A) HepG2 cells were pretreated with rotenone (0.1 μmol/L or 1.0 μmol/L, −30 min), then exposed to palmitate. Necrosis is demonstrated by Sytox Green staining.
Magnification 10×, scale bars 250 μm. (B) HepG2 cells were pretreated with rotenone (0.1 μmol/L or 1.0 μmol/L, −30 min) then exposed to palmitate. Apoptosis is
presented as caspase-3/7 activity. (C) Intracellular ROS production was measured after 12 h exposure to palmitate with or without pretreatment of rotenone. ROS
was measured by the intensity of DHE emission. * indicates P < 0.05; ns indicates P > 0.05.
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cells are one of the most commonly used substitutes for primary human
hepatocytes, especially for studies on hepatotoxicity in vitro. It is one of
the reasons that we choose HepG2 cells in this study. Besides, HepG2
cells also exhibit some metabolic features that are similar to in primary
hepatocytes. For example, the HepG2 cell line is one of the few cell lines
that demonstrate an insulin-stimulated increase of fatty acid uptake and
decrease of lipid secretion and is therefore frequently used to in-
vestigate insulin-dependent pathways [24]. However, because of its
tumorigenic origin, HepG2 cells show some differences compared to
primary hepatocytes with regard to metabolic pathways. One of the
differences is the utilization of glucose. HepG2 cells exhibit a greater
glucose incorporation rate [25], but impaired gluconeogenesis [24], as
well as a lower de novo lipogenesis ability to convert glucose to lipids
[25,26]. Besides, HepG2 cells have a lower fatty acid oxidation rate and
accumulate more lipids upon fatty acid treatment compared to primary
hepatocytes [25,26]. Upon palmitate challenge, we did observe some
Fig. 5. Effect of metformin and rotenone on the mitochondrial respiratory chain.
(A) An illustration graph of the calculation of basal respiration, proton leak and maximal respiration. (B, C) HepG2 cells were pretreated with metformin or rotenone,
then exposed to palmitate for 12 h. Real-time OCR was measured using XF24 analyzer. Injections include glucose (5 mmol/L), oligomycin (1 μmol/L), FCCP
(Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone, 0.25 μmol/L) and rotenone (1 μmol/L)/AA (antimycin, 1 μmol/L) sequentially. Basal respiration, proton
leak and maximal respiration were calculated to illustrate the difference in metabolic profile. (D) Primary rat hepatocytes were pretreated with metformin, then
exposed to palmitate (1.0 mmol/L) for 12 h. Real-time OCR was measured using XF24 analyzer. Data were shown as mean ± S.D. (n ≥ 3) * indicates P < 0.05; **
indicates P < 0.01; *** indicates P < 0.001.
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differences between these two cell types: palmitate induced both
apoptosis and necrosis in HepG2 cells, whereas it only induced necrosis
in primary rat hepatocytes. Moreover, primary rat hepatocytes ex-
hibited more severe damage of mitochondrial respiration (Fig. 5) and
depolarization of the mitochondrial membrane potential (Fig. 6) com-
pared to HepG2 cells, which might be explained by the higher fatty acid
oxidation rate of primary hepatocytes compared to hepatoma cell lines
[25,26].
Lipotoxicity is an important trigger of ER stress [27,28]. Saturated
fatty acids or their toxic metabolites can disrupt protein folding and ER-
to-Golgi trafficking resulting in activation of the unfolded protein re-
sponse (UPR) [27]. There are three major signaling arms in UPR sig-
naling that are initiated via three ER membrane associated proteins:
protein kinase RNA (PKR)-like ER kinase (PERK), inositol-requiring
kinase 1 (IRE1) and activating transcription factor 6 (ATF6). The PERK/
p-eIF2α arm is supposed to be the main signaling pathway related to
lipoapoptosis. Once activated, the PERK/p-eIF2α can transcriptionally
induce the expression of its downstream targets, including Gadd34,
GRP78 and CHOP, which also serve as markers to assess ER stress
[27,28]. A protective effect of metformin against palmitate-induced ER
stress has been reported in rat insulinoma cells [19]. Similarly, another
study showed that metformin inhibited lipotoxicity in hepatocytes by
reducing ER stress [20]. In our study, we also observed a reduction of p-
eIF2α upon treatment with metformin at 12 h. However, metformin did
not subsequently reduce CHOP, GRP78 and Gadd34 mRNA expression
at both 12 h and 16 h. The ER stress results reported in both papers
Fig. 6. Effect of Metformin and rotenone on mitochondrial membrane potential and ATP production.
HepG2 cells were pretreated with metformin or rotenone, then exposed to palmitate for 12 h. (A) HepG2 cells were stained by JC-10. Red emission indicates
mitochondrial membrane depolarization, green emission indicates mitochondrial membrane polarization. Magnification 10×. (B) Statistical analysis of the ag-
gregates/monomer fluorescence ratio. (C) ATP production was measured after 12 h of palmitate treatment in the presence and absence of metformin or rotenone.
Data were shown as mean ± S.D. (n ≥ 3) * indicates P < 0.05; ns indicates P > 0.05. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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mentioned above were at the protein level. Therefore, our results in-
dicate that the reduced activation of p-eIF2α did not lead to a reduction
of its downstream UPR signaling, suggesting that metformin does not
directly reduce ER stress and that the decreased phosphorylation of
eIF2α may be due to other mechanisms.
Another important target in lipotoxicity are mitochondria.
Mitochondria play a key role in the intrinsic pathway of apoptosis and
are one of the most important sources of ROS generation. Both clinical
studies and animal experiments have shown that there is a significant
increase in mitochondrial oxidative metabolism in NAFLD patients and
animal models [29,30]. The elevated TCA cycle flux and impaired mi-
tochondrial respiration chain could explain the common characteristic
of increased oxidative stress in NAFLD. Furthermore, we showed that
lowering the content of the intracellular antioxidant glutathione (GSH),
using the GSH synthesis inhibitor buthionine-sulfoximine (BSO), in-
creased palmitate-induced caspase-3/7 activity (Supplemental Fig. 2),
indicating an important role of ROS in promoting lipoapoptosis. On the
other hand, in our in vitro lipotoxicity model, the mitochondria showed
more pronounced malfunctioning, indicated by the depolarization of
the mitochondrial membrane potential and impaired mitochondrial
respiration. In addition, palmitate can initiate apoptotic cell death by
increasing cytochrome c release from mitochondria [31,32]. However,
whether targeting of mitochondria will be a therapeutic option is still
under investigation. Several studies showed that targeting different
mitochondrial components could be either protective or detrimental
[33–36]. In our present study, we found that moderate inhibition of
mitochondrial complex І (by metformin and rotenone at 0.1 μmol/L)
can protect against palmitate-induced cell death. However, a severe
inhibition (by rotenone at 1.0 μmol/L) was lethal. Although both
moderate and severe inhibition of mitochondrial complex І induce
SOD2 expression (part of the data unpublished), only moderate in-
hibition inhibits ROS production. Therefore, we hypothesize that
moderate inhibition of mitochondrial complex І preserves mitochon-
drial function which leads to a recovery of mitochondrial potential and
might relate to the increased expression of SOD2. In contrast, complete
inhibition of mitochondrial complex І leads to severe dysfunction of
mitochondria and aggravates cell death. This hypothesis is supported
by the fact that moderate inhibition of complex І resulted in a slight, but
not significant inhibition of ATP production, whereas, severe inhibition
of complex І caused a significant depletion of ATP, which could also
explain the different outcomes of two concentrations of rotenone. Of
note, metformin and low dose rotenone only induced expression of
SOD2, the mitochondrial isoform of SOD, but not the expression of
SOD1, the cytoplasmic isoform. These results further support the notion
that the mitochondria could be the first target of metformin in antag-
onizing lipotoxicity. We used two ROS scavengers (PEG-SOD and mito-
TEMPO) to mimic the protective effects of metformin. The mitochon-
drial specific ROS scavenger (mito-TEMPO) tended to reduce palmitate-
induced toxicity (data not shown) but only the general ROS scavenger
(PEG-SOD) significantly reduced palmitate-induced caspase 3/7 ac-
tivity, indicating that reduction of mitochondrial ROS production may
not be the (sole) mechanism for the protective effect of metformin.
Fig. 7. Metformin and rotenone (0.1 μmol/L) induced SOD2 mRNA and protein expression but did not induce SOD1 mRNA expression.
HepG2 cells were pretreated with metformin or rotenone, then exposed to palmitate for 12 h. (A) mRNA levels of SOD2 and SOD1 were measured and normalized
with 18S. (B) The immunofluorescence signals of SOD2 were quantified by fluorescence intensity. (C) HepG2 cells were pretreated with PEG-SOD (100 U/mL) for
30 min, then exposed to palmitate for 16 h. Caspase 3/7 activity was measured. Magnification 40×, scale bars 10 μm. Data were shown as mean ± S.D. (n ≥ 3). *
indicates P < 0.05; ** indicates P < 0.01; *** indicates P < 0.001; ns indicates P > 0.05.
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Metformin, as an inexpensive and widely accessible medicine, has
shown a broad application in diseases. In the treatment of NAFLD,
metformin presents beneficial effects in ameliorating hepatic steatosis
and inflammation [37,38]. Both animal experiments and clinical trials
have reported liver and body weight loss, histological improvement and
decrease in aminotransferases levels after metformin treatment
[23,37–40]. On the other hand, there are also clinical studies showing
that metformin demonstrated limited improvements in NAFLD patients
[41,42]. Given the dose-dependent results of rotenone in our present
study, we hypothesize that the dosage might play a critical role in the
actions of metformin. Since a proper inhibition of mitochondrial com-
plex І was vital to counter lipotoxicity, either too low or too high doses
of metformin may fail to show beneficial actions. Additionally, so far,
there is no study testing the inhibitory effect of metformin on mi-
tochondrial respiration in the context of NAFLD. Therefore, further
studies are needed to assess metformin as an option for the treatment of
NAFLD.
In conclusion, this study revealed that metformin protected against
palmitate-induced cell death in hepatocytes, in an AMPK-independent
manner, by partially inhibiting mitochondrial complex І, restoring mi-
tochondrial function and increasing SOD2 expression and ROS
scavenging. Furthermore, a low concentration of rotenone (0.1 μmol/L)
showed identical results, whereas a high concentration of rotenone
(1.0 μmol/L) exaggerated palmitate-induced cell death and failed to
restore mitochondrial function and reduce ROS. We conclude that
moderate inhibition of mitochondrial complex І promotes cell survival,
which may relate to the recovery of mitochondrial function and in-
duction of SOD2 expression. Taken together, metformin could be an
attractive candidate for the treatment of NASH/NAFLD. Furthermore,
mitochondrial complex І could be a potential therapeutic target in the
treatment of NAFLD.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbadis.2019.165621.
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